BIIB241227C120000
- 0.00
- 0.000.00%
Biogen Newsroom
Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
Express News | Eli Lilly and Co has launched a new drug for Alzheimer's disease: annual medication costs exceed 0.03 million dollars. Pfizer and Roche are making arrangements.
Investors Aren't Entirely Convinced By Biogen Inc.'s (NASDAQ:BIIB) Earnings
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More
Biogen Faces Multiple Analyst Downgrades in December 2024
BMO Capital has lowered the Target Price and rating for Bojian.
GeLong Hui December 23 | BMO Capital: Adjusted the Target Price for Bojien from 230 dollars to 164 dollars, and downgraded the rating from "Outperform" to "Market Perform." (GeLong Hui)
How to find the "alpha" market in U.S. stocks next year? Goldman Sachs provides an investment guide.
Zhihui Finance has learned that Goldman Sachs analysts said in a report that over the next six months, the materials, Software, and services industries in the USA are most likely to outperform the Large Cap. Goldman Sachs strategist David Kostin stated in a report on December 20 that they introduced a model for USA Stocks to select industries expected to exceed the benchmark Index by 5 percentage points or more, "to identify 'high conviction' views with significant Alpha potential." He noted, "Our model incorporates macro, fundamental, and valuation data as independent variables. We run probability models separately for each Industry, only including
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290
BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164
Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles
Biogen's Felzartamab: A Potential Blockbuster in Kidney Treatment With Unique Anti-CD38 Approach
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
BMO Cuts Rating on Merck and Biogen, on Lack of Near Term Catalyst
Biogen Cut to Market Perform From Outperform by BMO Capital
BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164
Express News | Bank of Montreal has downgraded Biogen to align with Large Cap, with a Target Price of 164 USD.
PTC Therapeutics Submits NDA for Friedreich Ataxia Treatment Vatiquinone
Eli Lilly Alzheimer's Therapy Approved in China